Sign In
Buy SNY
$43.75
-0.230 (-0.523%)
At Close: Jul 21, 2026
Sanofi Cancels Consumer Healthcare Business Spin-Off
02:28pm, Wednesday, 30'th Oct 2024
Deal Overview
Resalis Therapeutics Gains Strategic Equity Investment from Sanofi
06:00am, Monday, 28'th Oct 2024
TORINO, Italy--(BUSINESS WIRE)--Resalis Therapeutics announced today a strategic equity investment from Sanofi. The company intends to use the proceeds to accelerate the development of its lead invest
Why Sanofi Stock Flew Higher on Friday
05:23pm, Friday, 25'th Oct 2024
No investor can ignore a crushing bottom-line beat and raised profitability guidance.
Sanofi (SNY) Q3 2024 Earnings Call Transcript
01:36pm, Friday, 25'th Oct 2024
Sanofi (NASDAQ:SNY ) Q3 2024 Earnings Conference Call October 25, 2024 8:00 AM ET Company Participants Thomas Kudsk - Head of Investor Relations Paul Hudson - Chief Executive Officer Francois Roger -
Sanofi Q3 Earnings Beat, Dupixent, New Drugs, Vaccines Drive Sales
01:20pm, Friday, 25'th Oct 2024
SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat
09:11am, Friday, 25'th Oct 2024
Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales.
Sanofi CEO Paul Hudson on Q3 results: The modernization effort is starting to pay off
07:47am, Friday, 25'th Oct 2024
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, drug pipeline outlook, the company's Dupixent drug, and more.
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
07:18am, Friday, 25'th Oct 2024
On Friday, Sanofi SA SNY reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), up 14.4% year-over-year and 19.9% in constant currency.
Sanofi Q3 earnings beat market view, boosted by vaccine sales
01:32am, Friday, 25'th Oct 2024
French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by earlier-than-anticipated sales of seasonal vaccines.
Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
08:00am, Thursday, 24'th Oct 2024
Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved wel
Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake Sale
12:35pm, Monday, 21'st Oct 2024
SNY is negotiating with CD&R to sell a 50% stake in its consumer healthcare business, Opella.
French govt set to take stake in Sanofi unit after PE sale
03:06am, Monday, 21'st Oct 2024
France is reportedly set to acquire a small stake in Sanofi SA's (ADR) (NYSE:SNY) consumer healthcare unit as the pharmaceutical company proceeds with a €16 billion deal to sell half of the busine
Sanofi enters exclusive talks with CD&R for Opella sale
01:33am, Monday, 21'st Oct 2024
Sanofi said on Monday it had entered exclusive negotiations for the sale of a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R).
Press Release: Sanofi and CD&R partner to fuel Opella's ambitions in consumer healthcare
01:30am, Monday, 21'st Oct 2024
Sanofi and CD&R partner to fuel Opella's ambitions in consumer healthcare Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant
